User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

Interactions with Platform & by Email *

INTERACTIONS

Unique # Participated *

PARTICIPANTS

Responses Validated *

VALIDATIONS

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability And Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions And Scope Of Study.....I-3
Inhaled Corticosteroids:.....I-3
  
   Beta-2 Adrenoreceptor Agonists.....I-4
Combinations.....I-4
Anti- leukotrienes.....I-4
Others.....I-4
Antihistamines.....I-4
Methylxanthines.....I-4
  
   Mast Cell Stabilizers.....I-5
Monoclonal Antibodies.....I-5
Anticholinergics.....I-5
  
   Current & Future Analysis.....II-1
Competitive Outlook.....II-1
1$100
   Major Asthma Therapeutics by Class.....II-2
Facts about Asthma.....II-2
1$100
   Combination Drugs – Rule the World.....II-3
Novel Compounds To Pep Up Growth.....II-3
Rise in Pediatric Asthma To Keep Market Lucrative.....II-3
Toxic Nature of Asthma Drugs – A Serious Concern.....II-3
Life Threatening Drugs Under Regulatory Scan.....II-3
1$100
   Causes of Asthma.....II-4
Allergens.....II-4
Irritants.....II-4
Other Factors.....II-4
1$100
   Classes in Asthma.....II-5
A. Mild Intermittent Asthma: .....II-5
B. Mild Persistent Asthma: .....II-5
C. Moderate Persistent Asthma: .....II-5
D. Severe Persistent Asthma: .....II-5
1$100
   Asthma Treatments.....II-6
Combination Asthma Medications.....II-6
Over-the-Counter Asthma Medications.....II-6
Immunotherapy (Allergy shots).....II-6
Alternative Therapies.....II-6
Asthma Therapeutics.....II-6
1$100
   Corticosteroids.....II-7
Beta-2 Adrenoreceptor Agonists.....II-7
Mast Cell Stabilizers.....II-7
Monoclonal Antibodies.....II-7
Immune System: Natural Defenders.....II-7
1$100
   Human Antibodies.....II-8
Polyclonal and Monoclonal Antibodies.....II-8
Leukotriene Inhibitors.....II-8
Methylxanthines: .....II-8
Combination Therapeutics:.....II-8
Off Label Therapeutics:.....II-8
Anticholinergics: .....II-8
1$100
   Antihistamines: .....II-9
Asthma Therapeutics by Various Classes .....II-9
1$100
   Future to Witness A Novel Therapeutic in Asthma Treatment.....II-10
Dr. Reddy’s Releases Doxobid in India.....II-10
Novartis Files Approval for Xolair to Enter Japanese Market.....II-10
AstraZeneca Receives Approval for Symbicort.....II-10
GSK Alters Labels for Two Asthma Drugs.....II-10
1$100
   DMI BioSciences Starts Evaluating DMI 8393.....II-11
Inflazyme Begins Phase IIb Trial for IPL512,602.....II-11
Neurim Develops A Neuroprotective Compound.....II-11
Xolair® Forays into UK .....II-11
Critical Therapeutics Rolls Out ZYFLO®.....II-11
1$100
   Ivax Corp. Introduces Qvar EasiBreathe Inhaler.....II-12
Altana Rolls Out Respiratory Drug, Alvesco in the UK.....II-12
Sepracor Launches XOPENEX HFA.....II-12
Polyphor Commences Research for Protease Inhibitors.....II-12
Novartis Plans to Apply for A New Drug Approval.....II-12
Asmanex Twisthaler 220 mcg Receives US FDA Approval.....II-12
1$100
   GroPep Completes Pre-Clinical Testing of T-Cell Peptide Drug.....II-13
Able Laboratories Obtains FDA Approval .....II-13
Acceleration Therapeutics’ AT-101 Passes Laboratory Test .....II-13
Pharmaxis’ New Tool to Assess Asthma Passes Clinical Trial.....II-13
Aventis Seeks FDA Approval Alvesco®.....II-13
Schering-Plough Releases Asmanex Twisthaler.....II-13
1$100
   FDA Clears Xolair to Enter US Market.....II-14
Sepracor Completes Phase III Trial for XOPENEX.....II-14
Pfizer Conducts Phase II Clinical Studies.....II-14
Celera and Bayer Plans to End Collaboration.....II-14
Banyu and Kyorin Starts Distribution of Asthma Treatment.....II-14
GlaxoSmithKline Introduces Advair.....II-14
Novartis Gets FDA Approval for Foradil Aerolizer.....II-14
1$100
   Teva Purchases Ivax.....II-15
SkyePharma Strikes A Deal with KOSP.....II-15
Ranbaxy Inks an In-Licensing Agreement with Eurodrug.....II-15
Pfizer and Rigel Forms A Collaboration.....II-15
MAP and Elan Extends Agreement.....II-15
1$100
   Glenmark Collaborates with Teijin Pharma.....II-16
Pfizer Acquires Meridica.....II-16
Bayer and Apax Forms A New Company.....II-16
KOSP Signs Multiple Agreements.....II-16
1$100
   Novartis Pharma Inks A Licensing Agreement with Ivax.....II-17
LAB Intends to Purchase Seyvika.....II-17
ALTANA and Tanabe Signs A Pact.....II-17
1$100
   Abbott Laboratories (US).....II-18
ALTANA Pharma AG (Germany).....II-18
AstraZeneca (UK).....II-18
1$100
   Boehringer Ingelheim (Germany).....II-19
Genentech, Inc. (US).....II-19
GlaxoSmithKline (UK).....II-19
Merck & Co., Inc. (US).....II-19
Novartis Pharma AG (Switzerland).....II-19
1$100
   Pfizer Inc. (US).....II-20
Schering-Plough Corporation (US).....II-20
Sepracor Inc. (US).....II-20
1$100
   The Sanofi-Aventis Group (US).....II-21
3M (US).....II-21
1$100
   Table 1: World Recent Past, Current and Future Analysis for Asthma Therapeutics by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....II-22

Table 2: World 10-Year Perspective for Asthma Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....II-22
1$350
   Table 3: World Recent Past, Current and Future Analysis for Inhaled Corticosteroids by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....II-23

Table 4: World 10-Year Perspective for Inhaled Corticosteroids by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....II-23
1$350
   Table 5: World Recent Past, Current and Future Analysis for Short Acting Beta Agonists by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....II-24

Table 6: World 10-Year Perspective for Short Acting Beta Agonists by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....II-24
1$350
   Table 7: World Recent Past, Current and Future Analysis for Long Acting Beta Agonists by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....II-25

Table 8: World 10-Year Perspective for Long Acting Beta Agonists by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....II-25
1$350
   Table 9: World Recent Past, Current and Future Analysis for Combinations by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....II-26

Table 10: World 10-Year Perspective for Combinations by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....II-26
1$350
   Table 11: World Recent Past, Current and Future Analysis for Anti-Leukotrienes by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....II-27

Table 12: World 10-Year Perspective for Anti-Leukotrienes by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....II-27
1$350
   Table 13: World Recent Past, Current and Future Analysis for Other Asthma Therapeutics by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....II-28

Table 14: World 10-Year Perspective for Other Asthma Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....II-28
1$350
   A. Market Analysis.....III-1
Current & Future Analysis.....III-1
Asthma Reflections in the US.....III-1
Competitive Scenario.....III-1
Table 15: Leading Anticholinergic Companies in the US (2006): Percentage Breakdown of Market Share for Boehringer Ingelheim, Dey Inc, Alpharma and Others (includes corresponding Graph/Chart).....III-1
1$200
   Product Launches/Innovations.....III-22$150
   Strategic Developments.....III-41$75
   Focus on Key Players.....III-5
3M.....III-5
Abbott Laboratories.....III-5
Genentech, Inc......III-5
1$75
   Merck & Co., Inc......III-6
Pfizer Inc......III-6
Schering-Plough Corporation.....III-6
Sepracor Inc......III-6
1$75
   The Sanofi-Aventis Group.....III-71$75
   B. Market Analytics.....III-8
Table 16: US Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment – Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-8
1$200
   Table 17: US 10-Year Perspective for Asthma Therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....III-9
1$200
   A. Market Analysis.....III-10
Current & Future Analysis.....III-10
Product Launches/Innovations.....III-10
Strategic Development.....III-10
1$75
   B. Market Analytics.....III-11
Table 18: Canadian Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment – Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-11
1$200
   Table 19: Canadian 10-Year Perspective for Asthma Therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....III-12
1$200
   A. Market Analysis.....III-13
Current & Future Analysis.....III-13
Product Approvals/Launches.....III-13
Strategic Developments.....III-13
1$75
   B. Market Analytics.....III-14
Table 20: Japanese Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment – Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets IndependentlyAnalyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-14
1$200
   Table 21: Japanese 10-Year Perspective for Asthma Therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....III-15
1$200
   Market Analysis.....III-16
Current & Future Analysis.....III-16
Table 22: European Recent Past, Current and Future Analysis for Asthma Therapeutics by Geographic Region – France, Germany, UK, Italy, Spain and Rest of Europe Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-16
1$200
   Table 23: European Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment – Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-171$200
   Table 24: European 10-Year Perspective for Asthma Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, UK, Italy, Spain and Rest of Europe for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....III-181$200
   Table 25: European 10-Year Perspective for Asthma Therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....III-19
1$200
   Market Analysis.....III-20
Current & Future Analysis.....III-20
Table 26: French Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment – Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-20
1$200
   Table 27: French 10-Year Perspective for Asthma Therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....III-21
1$200
   A. Market Analysis.....III-22
Current & Future Analysis.....III-22
Product Launches/Innovations.....III-22
Focus on Key Players.....III-22
ALTANA Pharma AG.....III-22
Boehringer Ingelheim.....III-22
1$75
   B. Market Analytics.....III-23
Table 28: German Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment – Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-23
1$200
   Table 29: German 10-Year Perspective for Asthma Therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....III-24
1$200
   A. Market Analysis.....III-25
Current & Future Analysis.....III-25
Product Launches/Innovations.....III-25
1$75
   Strategic Developments.....III-26
Focus on Key Players.....III-26
AstraZeneca.....III-26
GlaxoSmithKline.....III-26
1$75
   B. Market Analytics.....III-27
Table 30: UK Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment – Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-27
1$200
   Table 31: UK 10-Year Perspective for Asthma Therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....III-28
1$200
   Market Analysis.....III-29
Current & Future Analysis.....III-29
Table 32: Italian Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment – Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-29
1$200
   Table 33: Italian 10-Year Perspective for Asthma Therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....III-30
1$200
   Market Analysis.....III-31
Current & Future Analysis.....III-31
Table 34: Spanish Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment – Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-31
1$200
   Table 35: Spanish 10-Year Perspective for Asthma Therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....III-32
1$200
   A. Market Analysis.....III-33
Current & Future Analysis.....III-33
Product Approvals/Launches.....III-33
1$75
   Strategic Development.....III-34
Focus on Select Player.....III-34
Novartis Pharma AG (Switzerland).....III-34
1$75
   B. Market Analytics.....III-35
Table 36: Rest of Europe Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment – Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-35
1$200
   Table 37: Rest of Europe 10-Year Perspective for Asthma Therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....III-36
1$200
   A. Market Analysis.....III-37
Current & Future Analysis.....III-37
Product Launches.....III-37
Strategic Developments.....III-37
1$75
   B. Market Analytics.....III-38
Table 38: Rest of World Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment – Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-38
1$200
   Table 39: Rest of World 10-Year Perspective for Asthma Therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....III-391$200